Literature DB >> 21325151

Genetic variations in the α(2A)-adrenoreceptor are associated with blood pressure response to the agonist dexmedetomidine.

Daniel Kurnik1, Mordechai Muszkat, Chun Li, Gbenga G Sofowora, Eitan A Friedman, Mika Scheinin, Alastair J J Wood, C Michael Stein.   

Abstract

BACKGROUND: α(2A)-Adrenoceptors (α(2A)-ARs) have important roles in sympathetic cardiovascular regulation. Variants of ADRA2A affect gene transcription and expression and are associated with insulin release and risk for type 2 diabetes. We examined whether ADRA2A variants are also associated with cardiovascular responses to the selective α(2)-AR-agonist dexmedetomidine. METHODS AND
RESULTS: Seventy-three healthy subjects participated in a placebo-controlled, single-blind study. After 3 infusions of placebo, subjects received 3 incremental infusions of dexmedetomidine (cumulative dose, 0.4 μg/kg). Primary outcomes were changes in systolic blood pressure (SBP) and plasma norepinephrine concentrations, measured as difference of the area-under-the-curve during placebo and dexmedetomidine infusions (ΔAUC). We used multiple linear regression analysis to examine the associations between 9 ADRA2A tagging variants and 5 inferred haplotypes and ΔAUC after adjustment for covariates. Homozygous carriers of rs553668 and the corresponding haplotype 4, previously associated with increased α(2A)-AR expression, had a 2.2-fold greater decrease in AUC(SBP) after dexmedetomidine (adjusted P=0.006); similarly, the maximum decrease in SBP was 24.7±8.1 mm Hg compared with 13.6±5.9 mm Hg in carriers of the wild-type allele (P=0.007). Carriers of haplotype 3, previously associated with reduced α(2A)-AR expression, had a 44% smaller decrease in AUC(SBP) (P=0.013). Haplotype information significantly improved the model predicting the decrease in SBP (P<0.001). There were similar but nonsignificant trends for diastolic blood pressure and heart rate. Genotypes were not significantly associated with norepinephrine responses.
CONCLUSIONS: Common ADRA2A variants are associated with the hypotensive response to dexmedetomidine. Effects of specific variants/haplotypes in vivo are compatible with their known effects on gene expression in vitro.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21325151      PMCID: PMC3080459          DOI: 10.1161/CIRCGENETICS.110.957662

Source DB:  PubMed          Journal:  Circ Cardiovasc Genet        ISSN: 1942-3268


  29 in total

1.  Sympathoinhibitory function of the alpha(2A)-adrenergic receptor subtype.

Authors:  K P Makaritsis; C Johns; I Gavras; J D Altman; D E Handy; M R Bresnahan; H Gavras
Journal:  Hypertension       Date:  1999-09       Impact factor: 10.190

2.  Do allelic variants in alpha2A and alpha2C adrenergic receptors predispose to hypertension in blacks?

Authors:  Jia-Ling Li; Russell M Canham; Wanpen Vongpatanasin; David Leonard; Richard J Auchus; Ronald G Victor
Journal:  Hypertension       Date:  2006-04-24       Impact factor: 10.190

3.  Haplotype-based analysis of alpha 2A, 2B, and 2C adrenergic receptor genes captures information on common functional loci at each gene.

Authors:  Inna Belfer; Beata Buzas; Heather Hipp; Gabriel Phillips; Julie Taubman; Ilona Lorincz; Catherine Evans; Robert H Lipsky; Mary-Anne Enoch; Mitchell B Max; David Goldman
Journal:  J Hum Genet       Date:  2004-12-08       Impact factor: 3.172

4.  Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission.

Authors:  L Hein; J D Altman; B K Kobilka
Journal:  Nature       Date:  1999-11-11       Impact factor: 49.962

5.  Functional correlates of alpha(2A)-adrenoceptor gene polymorphism in the HANE study.

Authors:  M C Michel; C Plogmann; T Philipp; O E Brodde
Journal:  Nephrol Dial Transplant       Date:  1999-11       Impact factor: 5.992

6.  Complex haplotypes derived from noncoding polymorphisms of the intronless alpha2A-adrenergic gene diversify receptor expression.

Authors:  Kersten M Small; Kari M Brown; Carrie A Seman; Cheryl T Theiss; Stephen B Liggett
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

7.  Abnormal regulation of the sympathetic nervous system in alpha2A-adrenergic receptor knockout mice.

Authors:  J D Altman; A U Trendelenburg; L MacMillan; D Bernstein; L Limbird; K Starke; B K Kobilka; L Hein
Journal:  Mol Pharmacol       Date:  1999-07       Impact factor: 4.436

8.  Effects of variation in the human alpha2A- and alpha2C-adrenoceptor genes on cognitive tasks and pain perception.

Authors:  Utkarsh Kohli; Mordechai Muszkat; Gbenga G Sofowora; Paul A Harris; Eitan A Friedman; William D Dupont; Mika Scheinin; Alastair J J Wood; C Michael Stein; Daniel Kurnik
Journal:  Eur J Pain       Date:  2009-05-06       Impact factor: 3.931

9.  Alpha 2-adrenergic receptor gene polymorphism and hypertension in blacks.

Authors:  W Lockette; S Ghosh; S Farrow; S MacKenzie; S Baker; P Miles; A Schork; L Cadaret
Journal:  Am J Hypertens       Date:  1995-04       Impact factor: 2.689

10.  Variations in the alpha2A-adrenergic receptor gene and their functional effects.

Authors:  Daniel Kurnik; Mordechai Muszkat; Chun Li; Gbenga G Sofowora; Joseph Solus; Hong-Guang Xie; Paul A Harris; Lan Jiang; Chara McMunn; Patrick Ihrie; Elliott P Dawson; Scott M Williams; Alastair J J Wood; C Michael Stein
Journal:  Clin Pharmacol Ther       Date:  2006-02-07       Impact factor: 6.875

View more
  12 in total

1.  Evaluation of the association between the ADRA2A genetic polymorphisms and type 2 diabetes in a Chinese Han population.

Authors:  Tianjie Li; Xilin Zhu; Xiaopan Wu; Jingyun Li; Liping Pan; Pengtao Li; Zhenhui Xin; Harvest F Gu; Ying Liu
Journal:  Genet Test Mol Biomarkers       Date:  2012-12

2.  The Efficacy and Safety of Dexmedetomidine for Procedural Sedation in Patients Receiving Local Anesthesia Outside the Intensive Care Unit: A Prospective, Double-Blind, Randomized Clinical Phase III Trial in Japan.

Authors:  Yoshimi Inagaki; Kiyoshi Morita; Makoto Ozaki; Kazuo Matsumoto; Akifumi Okayama; Nobuyo Oya; Takehiko Hiraoka; Junzo Takeda
Journal:  Yonago Acta Med       Date:  2022-01-21       Impact factor: 1.641

Review 3.  Adrenergic receptors gene polymorphisms and autonomic nervous control of heart and vascular tone.

Authors:  L Matušková; M Javorka
Journal:  Physiol Res       Date:  2021-12-30       Impact factor: 2.139

4.  Alpha2A adrenergic receptor genetic variation contributes to hyperglycemia after myocardial infarction.

Authors:  Abiodun Adefurin; Leon Darghosian; Chimalum Okafor; Vivian Kawai; Chun Li; Anushi Shah; Wei-Qi Wei; Daniel Kurnik; C Michael Stein
Journal:  Int J Cardiol       Date:  2016-04-13       Impact factor: 4.164

5.  Variation in the α(2A) adrenoceptor gene and the effect of dexmedetomidine on plasma insulin and glucose.

Authors:  Laxmi V Ghimire; Mordechai Muszkat; Gbenga G Sofowora; Mika Scheinin; Alastair J J Wood; C Michael Stein; Daniel Kurnik
Journal:  Pharmacogenet Genomics       Date:  2013-09       Impact factor: 2.089

6.  ADRA2A Germline Gene Polymorphism is Associated to the Severity, but not to the Risk, of Breast Cancer.

Authors:  Batoul Kaabi; Ghania Belaaloui; Wassila Benbrahim; Kamel Hamizi; Mourad Sadelaoud; Wided Toumi; Hocine Bounecer
Journal:  Pathol Oncol Res       Date:  2015-11-13       Impact factor: 3.201

7.  Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome.

Authors:  Sara L Van Driest; Lynn A Sleeper; Bruce D Gelb; Shaine A Morris; Harry C Dietz; Geoffrey A Forbus; Elizabeth Goldmuntz; Arvind Hoskoppal; Jeanne James; Teresa M Lee; Jami C Levine; Jennifer S Li; Bart L Loeys; Larry W Markham; Josephina A N Meester; Seema Mital; Jonathan D Mosley; Aaron K Olson; Marjolijn Renard; Christian M Shaffer; Angela Sharkey; Luciana Young; Ronald V Lacro; Dan M Roden
Journal:  J Pediatr       Date:  2020-07       Impact factor: 4.406

8.  Alpha2A-adrenergic receptor and eNOS genetic polymorphisms are associated with exercise muscle vasodilatation in apparently healthy individuals.

Authors:  Rafael Amorim Belo Nunes; Lucia Pereira Barroso; Alexandre da Costa Pereira; Maria Urbana Pinto Brandão Rondon; Carlos Eduardo Negrão; José Eduardo Krieger; Alfredo José Mansur
Journal:  Int J Cardiol Heart Vasc       Date:  2016-10-13

Review 9.  Interpatient variability in dexmedetomidine response: a survey of the literature.

Authors:  Samantha F Holliday; Sandra L Kane-Gill; Philip E Empey; Mitchell S Buckley; Pamela L Smithburger
Journal:  ScientificWorldJournal       Date:  2014-01-16

Review 10.  Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes.

Authors:  Michelle E Kimple; Joshua C Neuman; Amelia K Linnemann; Patrick J Casey
Journal:  Exp Mol Med       Date:  2014-06-20       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.